Jefferies Group's BBIO Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 200,000 shares of BridgeBio Pharma, Inc. (BBIO) worth $15.3 M, representing 0.08% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in BBIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 200,000 shares. Largest reduction occurred in Q3 2023, reducing 213,049 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's BridgeBio Pharma (BBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly BridgeBio Pharma (BBIO) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +200,000 | New Buy | 200,000 | $76.49 |
| Q1 2025 | -185,000 | Sold Out | 0 | $0.00 |
| Q4 2024 | +185,000 | New Buy | 185,000 | $27.44 |
| Q2 2024 | -61,907 | Sold Out | 0 | $0.00 |
| Q1 2024 | -41,840 | Reduce 40.33% | 61,907 | $30.92 |
| Q4 2023 | +44,558 | Add 75.28% | 103,747 | $40.37 |
| Q3 2023 | -213,049 | Reduce 78.26% | 59,189 | $26.37 |
| Q2 2023 | +111,868 | Add 69.76% | 272,238 | $17.20 |
| Q1 2023 | +160,370 | New Buy | 160,370 | $16.58 |
Jefferies Group's BridgeBio Pharma Investment FAQs
Jefferies Group first purchased BridgeBio Pharma, Inc. (BBIO) in Q1 2023, acquiring 160,370 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held BridgeBio Pharma, Inc. (BBIO) for 9 quarters since Q1 2023.
Jefferies Group's largest addition to BridgeBio Pharma, Inc. (BBIO) was in Q4 2025, adding 200,000 shares worth $15.3 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 200,000 shares of BridgeBio Pharma, Inc. (BBIO), valued at approximately $15.3 M.
As of the Q4 2025 filing, BridgeBio Pharma, Inc. (BBIO) represents approximately 0.08% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in BridgeBio Pharma, Inc. (BBIO) was 272,238 shares, as reported at the end of Q2 2023.